Curriculum Vitae Europass - Visite Private

Curriculum Vitae
Europass
Informazioni personali
Cognome(i) / Nome(i)
Data di nascita
ENRICA MORRA
16 settembre 1948
Esperienza professionale
Date
Lavoro o posizione ricoperti
Nome e indirizzo del datore di lavoro
Date
Lavoro o posizione ricoperti
Nome e indirizzo del datore di lavoro
Date
Lavoro o posizione ricoperti
Nome e indirizzo del datore di lavoro
Date
Lavoro o posizione ricoperti
Nome e indirizzo del datore di lavoro
Dal 2000 ad oggi
Direttore del Dipartimento Oncologico
AO Niguarda Ca’ Granda, Milano
Dal 1994 ad oggi
Direttore Struttura Complessa di Ematologia
AO Niguarda Ca’ Granda, Milano
1984 - 1994
Aiuto Ematologo a tempo pieno
Struttura Complessa di Ematologia
Istituto Scientifico Policlinico San Matteo, Pavia
1973 - 1984
Assistente Ematologo a tempo pieno
Istituto Scientifico Policlinico San Matteo, Pavia
Istruzione e formazione
Date
Titolo della qualifica rilasciata
Nome e tipo d'organizzazione
erogatrice dell'istruzione e formazione
Date
Titolo della qualifica rilasciata
Nome e tipo d'organizzazione
erogatrice dell'istruzione e formazione
Date
Titolo della qualifica rilasciata
Nome e tipo d'organizzazione
erogatrice dell'istruzione e formazione
Pagina 1 / 8 - Curriculum vitae di
Morra Enrica
1982
Specializzazione in Oncologia
Università di Pavia
1975
Specializzazione in Ematologia
Università di Pavia
1966 - 1972
Laurea in Medicina e Chirurgia
Università di Pavia
Per maggiori informazioni su Europass: http://europass.cedefop.europa.eu
© Unione europea, 2002-2010 24082010
Capacità e competenze
personali
Madrelingua(e)
Italiano
Altra(e) lingua(e)
Comprensione
Autovalutazione
Ascolto
Livello europeo (*)
Inglese
Lettura
Parlato
Interazione orale
Scritto
Produzione orale
B2 Utente autonomo B2 Utente autonomo B2 Utente autonomo B2 Utente autonomo B2 Utente autonomo
(*) Quadro comune europeo di riferimento per le lingue
Ulteriori informazioni
−
−
Società Italiana di Ematologia (SIE) 1982 - attualmente
Società Americana di Ematologia (ASH) 1986– attualmente
−
Docente presso la scuola di specializzazione in Ematologia dell’Università di Pavia 1989–
attualmente
Docente presso la scuola di specializzazione in Ematologia dell’Università di Milano 1997 attualmente
−
−
−
−
Commissione Regionale GAT per l’Ematologia 2008 - attualmente
Commissione Regionale Ematologia
1998 – attualmente
Coordinatore Scientifico per la Rete Ematologica Lombarda 2008 - attualmente
Autorizzo il trattamento dei miei dati personali ai sensi del Decreto Legislativo 30 giugno 2003, n. 196 "Codice in materia di protezione dei dati
personali (facoltativo)"
Data e Firma
15/03/2012
Pagina 2 / 8 - Curriculum vitae di
Morra Enrica
Per maggiori informazioni su Europass: http://europass.cedefop.europa.eu
© Unione europea, 2002-2010 24082010
Dr. Enrica Morra: Pubblicazioni (dal 2002)
1.
Lazzarino M, Arcaini L, Bernasconi P, Alessandrino EP, Gargantini L, Cairoli R, Orlandi E, Astori C, Brusamolino E, Pagnucco G, Colombo AA, Calatroni S, Iacona I,
Regazzi MB, Morra E. A sequence of immuno-chemotherapy with Rituximab, mobilization of in vivo purged stem cells, high-dose chemotherapy and
autotransplant is effective and non-toxic treatment for advanced follicular and mantle cell lymphoma. Br J Haematol 2002, 116, 229-235
2.
Muti G, Cantoni S, Oreste P, Gini G, Rossi V, D’Avanzo G, Montillo M, Nosari A, Morra E, for the Cooperative Study group on PTLD. Post-transplant
lymphoproliferative disorders (PTLD) in solid organ recipients: clinico-pathological feaatures and outcome in a group of 30 patients. Haematologica 2002:87:7888
3.
Corso A, Arcaini L, Caberlon S, Zappasodi P, Mangiacavalli S, Lorenzi A, Rusconi C, Troletti D, Maiocchi MA, Pascutto C, Morra E, Lazzarino M. A combination of
dexamethasone, cyclophosphamide, etoposide, and cisplatin is less toxic and more effective than high-dose cyclophosphamide for peripheral stem cell
mobilization in multiple myeloma. Haematologica 2002 Oct;87(10):1041-5
4.
Cesana C, Klersy C, Barbarano L, Nosari AM, Crugnola M, Pungolino E, Gargantini L, Granata S, Valentini M, Morra E. Prognostic factors for malignant
transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. J Clin Oncol, 2002,20: 1625-1634.
5.
Cairoli R, Grillo G, Tedeschi A, Gargantini L, Marenco P, Tresoldi E., Barbarano L, Nosari AM, Morra E Efficacy of an early intensification treatment integrating
chemotherapy, autologous stem cell transplantation and radiotharapy for poor risk primary mediastinal large B cell lymphoma with sclerosis.. BMT 2002, 29:
473-477
6.
Cesana C, Brando B, Boiani E, Chiodo F, Cairoli R, Intropido L, Morra E. Effective treatment of autoimmune hemolytic anemia and hairy cell leukemia with
interferon-α. Eur J Haematol 2002:68: 1-7
7.
Sawyers CL, Hochhaus A, Feldman E, Goldman JM, Miller CB, Ottmann OG, Schiffer CA, Talpaz M, Guilhot F, Deininger MWN, Fischer T, O’Brien SG, Stone RM,
Gambacorti Passerini CB, Russel NH, Reiffers J, Shea TC, Chapuis , Coutre S, Tura S, Morra E, Larson RA, Seven A, Peschel C, Gratwhol A, Mandelli F, Ben-Am M,
Gathmann I, Capdeville R, Paquette RL, Druker BJ. Imatinib induces hematologic and cytogenetic respsonses in patients with chronic myelogenous leukemia in
myeloid blast crisis: results of a phase II study. Blood 2002; 99: 3530-3539
8.
Alessandrino EP, Amadori S, Cazzola M, Locatelli F, Mecucci C, Morra E, Saglio G, Visani G, Tura S. Myelodysplastic syndromes: recent advances. Haematologica
2001; 86:1124-1157
9.
Montillo M, Cafro AM, Tedeschi A, Brando B, Oreste P, Veronese S, Rossi V, Cairoli R, Pungolino E, Morra E. Safety and efficacy of subcutaneous Campath-1H
for treating residual disease in patients with chronic lymphocytic leukemia responding to fludarabine. Haematologyca July 2002; 87: 695-700
10. Rambaldi A, Lazzari M, Manzoni C, Carlotti E, Arcaini L, Baccarani M, Barbui T, Bernasconi C, Dastoli G, Fuga G, Gamba E, Gargantini L, Gattei V, Lauria F,
Lazzarino M, Mandelli F, Morra E et al. Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular
lymphoma. Blood, 2002; 99:856-862
11. Silini E, Locasciulli A, Santoleri L, Gargantini L, Pinzello G, Montillo M, Foti L, Lisa A, Orfeo N, Magliano E, Nosari A, Morra E. Hepatitis C virus infection in a
hematology ward: evidence for nosocomial transmission and impact on hematologic disesase outcome. Haematologica vol. 87(11): november 2002
12. Montillo M, Tedeschi A, O’Brien S, Di Raimondo F, Lerner S, Ferrajoli A, Morra E, Keating JK. Phase II study of cladribine and cyclophosphamide in patients with
chronic lymphocytic leukemia and prolymphocytic leukemia. Cancer 2003; 97:114-20.
13. Tedeschi A, Cairoli R, Marenco P, Nosari A, Tresoldi E, Di Bona E, Montillo M and Morra E. Molecular remission and reconstitution of a full chimera with arsenic
trioxide in a patient with acute promyelocytic leukemia relapsed after allogenic bone marrow transplantation. Leukemia 2002; 16:2455-56.
14. Tedeschi A, Montillo A, Cairoli R, Marenco P, Cafro A, Oreste P, Nosari A and Morra E. Prior invasive pulmonary and cerebellar mucormycosis is not a primary
contraindication to perform an autologous stem cell transplantation in leukemia. Leukemia and Lymphoma 2002; vol 43 (3): 657-659.
15. Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C, Niederwieser D, Resta D, Capdeville R, Zoellner U, Talpaz M, Druker B,
Goldman J, O'Brien SG, Russell N, Fischer T, Ottmann O, Cony-Makhoul P, Facon T, Stone R, Miller C, Tallman M, Brown R, Schuster M, Loughran T, Gratwohl A,
Mandelli F, Saglio G, Lazzarino M, Russo D, Baccarani M, Morra E; International STI571 CML Study Group. Hematologic and cytogenetic responses to imatinib
mesylate in chronic myelogenous leukemia. N Engl J Med 2002;346(9):645-52
16. Nosari A, Bernuzzi P, Corneo R, Pungolino E, Muti G, Rossi V, Morra E. late response to cyclosporine in refractory thrombocit thrombocytopenic purpura. Int J
Hematol 2002; 76(3): 284-6
17. Ferrari D, Girmenia G, Migliorini L, Nosari A, Morra E. Hepatosplenic gamma delta T-cell lymphoma with a novel cytogenetic alteration and crebrospinal fluid
infiltration: biological and clinical features. Haematologica, 2002; 87(3): ECR11
18. Cesana C, Brando B, Boiani E, Chiodo F, Cairoli R, Intropido L, Morra E. Effective treatment of autoimmune hemolytic anemia and hairy cell leukemia with
interferon-alpha. Eur J Haematol 2002; 68(2): 120-1
19. Doneda L, Montillo M, Intropido L, Tedeschi A, Morra E, Larizza L. Interphase fluorescence in situ hybridization analysis of del(11)(q23) an del(17)(p13) in
chronic lymphocytic leukemia a study of 40 early-onset patients. Cancer Genet Cytogenet 2003; Jan 1; 140(1):31-6
20. Locasciulli A, Bruno B, Alessandrino EP, Meloni G, Arcese W, Bandini G, Cassibba V, Rotoli B, Morra E, Majolino I, Alberti A, Bacigalupo A. Hepatitis reactivation
and liver failure in haemopoietic stem cell transplants for hepatitis B virus (HBV)/hepatitis C virus (HCV) posititve recipients: a retrospective study by the italian
group for blood and marrow transplantation. BMT 2003; 31(4):295-300
21. Marbello L, Nosari A, Carrafiello G, Anghilieri M, Cesana C, Cafro AM, D’Avanzo G, Morra E. Successful treatment with voriconazole of cerebral aspergillosis in
an hematologic patient. Haematologica 2003; 88(3): ECR05
22. Foa R, Vitale A, Mancini M, Cuneo A, Mecucci C, Elia L, Lombardo R, Saglio G, Torelli G, Annino L, Specchia G, Damasio E, Recchia A, Di Raimondo F, Morra E,
Volpe E, Tafuri A, Fazi P, Hunger SP, Mandelli F. E2A-PBX1 fusion in adult acute lymphoblastic leukaemia: biological and clinical features. Br J Haematol, 2003,
120:484-487
23. Cairoli R, Grillo G, Beghini A, Tedeschi A, Ripamonti CB, Larizza L, Morra E. C-Kit point mutation in core binding factor leukemias: correlation with white blood
cell conunt and the white blood cell index.. Leukemia 2003; 17, 471-472
Pagina 3 / 8 - Curriculum vitae di
Morra Enrica
Per maggiori informazioni su Europass: http://europass.cedefop.europa.eu
© Unione europea, 2002-2010 24082010
24. E Silini, A Locasciulli, L Santoleri, L Gargantini, G Pinzello, M Montillo, L Foti, A Lisa, N Orfeo, E Magliano, A Nosari, E Morra. Hepatitis C virus infection in a
hematology ward: evidence for nosocomial transmission and impact on hematologic disease outcome. Haematologica, vol. 87(11): 2002
25. C Cesana, S Miqueleiz, P Bernuzzi, E Tresoldi, V Rossi, G D’Avanzo, D Filippini, E Morra. Smouldering Waldenstrom’s Macroglobulinemia: factors predicting
evolution to symptomatic disease. Sem Oncol, vol. 30, No 2, 2003
26. E Morra, C Cesana, C Klersy, M Varettoni, L Cavanna, B Canesi, E Tresoldi, L Barbarano, M Lazzarino. Predictive variables for malignant transformation in 452
patients with asymptomatic IgM monoclonal gammopathy. Sem Oncol, vol. 30, No 2, 2003
27. Cappello D, Cerri M, Muti G, Berra E, Oreste P, Deambrogi C, Rossi D, Dotti G, Conconi A, Vigano M, Magrini U, Ippoliti G, Morra E et al. Molecular histogenesis
of post transplantation lymphoproliferative disorders. Blood, Nov 15;102(10):3775-85, 2003
28. Muti G, Klersy C, Baldanti F, Granata S, Oreste P, Pezzetti L, Gatti M, Gargantini L, Caramella M, Mancini V, Gerna G, Morra E. Co-operative Study Group on
PTLDs. Epstain Barr virus (EBV) load and interleukin-10 in EBV-positive and EBV-negative post-transplant lymphoproliferative disorders. Br J Haematol,
122(6):927-33, 2003
29. Cesana C, Nosari AM, Klersy C, Miqueleiz S, Rossi V, Ferrando P, Valentini M, Barbarano L, Morra E. Risk factors for the development of bacterial infections in
multiple myeloma treated with two different vincristine-adriamycin-dexamethasone schedules. Haematologica, 88(9):1022-8, 2003
30. Passamonti F Vanelli L, Malabarba L, Rumi E, Pungolino E, Malcovati L, Pascutto C, Morra E, Lazzarino M, Cazzola M. Clinical utility of the absolute number of
circulating CD34-positive cells in patients with chronic myeloproliferative disorders. Haematologica, 88(9):1022-8, 2003
31. Rossi D, Gaidano G, Gloghini A, Deambrogi C, Fanceschetti S, Berra E, Cerri M, Vendramin C, Conconi A, Viglio A, Muti G, Oreste P, Morra E et al. Frequent
aberrant promoter hypermethylation of 06-methylguanine-DNA methyltransferase and death-associated protein kinase genes in immunodeficiency-related
lymphomas. Br J Haematol, 123(3):475-8, 2003
32. Nosari A, Anghilieri M, Carrafiello G, Guffanti C, Marbello L, Montillo M, Muti G, Ribera S, Vanzulli A, Nichelatti M, Morra E. Utility of percutaneuos lung biopsy
fro diagnosing filamentous fungal infections in hematologic malignancies. Haematologica, 88(12):1405-9, 2003
33. Cozzi P, Nosari A, Cantoni S, Ribera S, Pungolino E, Lizzadro G, Oreste P, Asnaghi D, Morra E. Traumatic left shoulder fracture masking aggressive granuloblastic
sarcoma in a CML patients. Haematologica 89(7), 2004
34. Cairoli R, Grillo G, Tedeschi A, D’Avanzo G, Marenco P, Morra E. High incidence of neutropenia in patients treated with rituximab after autologous stem cell
transplantation. Haematologica, 89(3):361-3, 2004
35. Nosari A, Marbello L, De Carlis LG, De Gasperi A, Muti G, Mancini V, Morra E. Bone marrow hypoplasia complicating tacrolimus (FK506) therapy. Int J Hematol,
79(2):130-2, 2004
36. Forconi F, CapelloD, Berra E, Rossi D, Gloghini A Cerri M, Muti G, Morra E et al. Incidence of novel N-glycosylation sites in the B-cell receptor of lymphomas
associated with immunodeficiency. Br J Haematol, 124(5):604-9; 2004
37. Morra E, Montillo M. Chronic lymphocytic leukemia 2003. Haematologica, 89(1)9-10, 2004.
38. Todeschini G, Secchi S, Morra E et al. Primary mediastinal large B-cell lymphoma (PMLBCL): long-term results from a retrospective multicentre Italian
experience in 138 patients treated with CHOP or MACOP-B/VACOP-B. Br J Cancer, 26;90(2):372-6, 2004
39. Montillo M, Tedeschi A, Rossi V, Cairoli R, Pungolino E, Intropido L, Cafro AM, D’Avanzo G, Farioli R, Brando B, Scarpati B, Veronese S, Morra E. Successful
CD34+ cell mobilization by intermediate-dose Ara-C in chronic lymphocytic leukemia patients treated with sequential fludarabine and Campath-1H. Leukemia,
18(1):57-62, 2004
40. Morra E, Cesana C, Klersy C, Barbarano L, Varettoni M, Cavanna L, Canesi B, Tresoldi E, Miqueleiz S, Bernuzzi P, Nosari AM, Lazzarino M on behalf of the HOST
(Hematology/Oncology Studies and Trials) Group. Clinical characteristics and factors predicting evolution of asymptomatic IgM monoclonal gammopathies and
IgM-related disorders. Leukemia 2004, in press
41. Gobbi PG, Baldini L, Broglia C, Goldaniga M, Comelli M, Morel P, Morra E, Cortelazzo S, Bettini R, Merlini G. Prognognostic validation of the international
classification of immunoglobulin M gammopaties: a survival advantage for patients with immunoglobulin M monoclonal gammopathy of undetermined
significance? Clinical Cancer Research, 11: 1786-90, 2005
42. Cairoli R, Beghini A, Grillo G, Nadali G, Elice F, Ripamonti CB, Colapietro P, Nichelatti M, Pezzetti L, Lunghi M, Cuneo A, Viola A, Ferrara F, Lazzarino M,
Rodeghiero F, Pizzolo G, Larizza L, Morra E. Prognostic impact of c-KIT mutations in core binding factor leukemias. an Italian retrospective study. Blood. 2005
Dec 29;
43. Redaelli R, Corno AR, Borroni L, Mostarda G, Nichelatti M, Morra E, Baudo F. von Willebrand factor ristocetin cofactor (VWF:RCo) assay: implementation on an
automated coagulometer (ACL). J Thromb Haemost. 2005 Dec;3(12):2684-8.
44. Regazzi MB, Iacona I, Avanzini MA, Arcaini L, Merlini G, Perfetti V, Zaja F, Montagna M, Morra E, Lazzarino M. Pharmacokinetic behavior of rituximab: a study of
different schedules of administration for heterogeneous clinical settings. Ther Drug Monit. 2005 Dec;27(6):785-92.
45. Morra E. Cryoglobulinemia. Hematology (Am Soc Hematol Educ Program). 2005;:368-72.
46. Muti G, Mancini V, Ravelli E, Morra E. Significance of Epstein-Barr virus (EBV) load and interleukin-10 in post-transplant lymphoproliferative disorders. Leuk
Lymphoma. 2005 Oct;46(10):1397-407. Review.
47. Corso A, Mangiacavalli S, Nosari A, Castagnola C, Zappasodi P, Cafro AM, Astori C, Bonfichi M, Varettoni M, Rusconi C, Troletti D, Pascutto C, Morra E, Lazzarino
M; HOST Group. Efficacy, toxicity and feasibility of a shorter schedule of DCEP regimen for stem cell mobilization in multiple myeloma. Bone Marrow
Transplant. 2005 Dec;36(11):951-4.
48. Molteni A, Nosari A, Montillo M, Cafro A, Klersy C, Morra E. Multiple lines of chemotherapy are the main risk factor for severe infections in patients with
chronic lymphocytic leukemia with febrile episodes. Haematologica. 2005 Aug;90(8):1145-7.
49. Baldini L, Goldaniga M, Guffanti A, Broglia C, Cortelazzo S, Rossi A, Morra E, Colombi M, Callea V, Pogliani E, Ilariucci F, Luminari S, Morel P, Merlini G, Gobbi P.
Immunoglobulin M monoclonal gammopathies of undetermined significance and indolent Waldenstrom's macroglobulinemia recognize the same determinants
Pagina 4 / 8 - Curriculum vitae di
Morra Enrica
Per maggiori informazioni su Europass: http://europass.cedefop.europa.eu
© Unione europea, 2002-2010 24082010
of evolution into symptomatic lymphoid disorders: proposal for a common prognostic scoring system. J Clin Oncol. 2005 Jul 20;23(21):4662-8.
50. Beghini A, Bellini M, Magnani I, Colapietro P, Cairoli R, Morra E, Larizza L. STI 571 inhibition effect on KITAsn822Lys-mediated signal transduction cascade. Exp
Hematol. 2005 Jun;33(6):682-8.
51. Perego RA, Cairoli R, Cornacchini G, Bianchi C, Corizzato M, Tresoldi E, Morra E. The role of quantitative polymerase chain reaction in the management of
follicular lymphoma patients. Tumori. 2005 Jan-Feb;91(1):59-66.
52. Morra E, Cesana C, Klersy C, Barbarano L, Miqueleiz S, Varettoni M, Lucchesini C, Ricci F, Lazzarino M. Prognostic factors for transformation in asymptomatic
immunoglobulin m monoclonal gammopathies. Clin Lymphoma. 2005 Mar;5(4):265-9.
53. Cesana C, Barbarano L, Miqueleiz S, Lucchesini C, Ricci F, Varettoni M, Filippini D, Lazzarino M, Morra E. Clinical characteristics and outcome of immunoglobulin
M-related disorders. Clin Lymphoma. 2005 Mar;5(4):261-4.
54. Gobbi PG, Baldini L, Broglia C, Goldaniga M, Comelli M, Morel P, Morra E, Cortelazzo S, Bettini R, Merlini G. Prognostic validation of the international
classification of immunoglobulin M gammopathies: a survival advantage for patients with immunoglobulin M monoclonal gammopathy of undetermined
significance? Clin Cancer Res. 2005 Mar 1;11(5):1786-90.
55. Montillo M, Hamblin T, Hallek M, Montserrat E, Morra E. Chronic lymphocytic leukemia: novel prognostic factors and their relevance for risk-adapted
therapeutic strategies. Haematologica. 2005 Mar;90(3):391-9.
56. Cairoli R, Beghini A, Morello E, Grillo G, Montillo M, Larizza L, Morra E. Imatinib mesylate in the treatment of Core Binding Factor leukemias with KIT mutations.
A report of three cases. Leuk Res. 2005 Apr;29(4):397-400. Epub 2005 Jan 12.
57. Rambaldi A, Carlotti E, Oldani E, Della Starza I, Baccarani M, Cortelazzo S, Lauria F, Arcaini L, Morra E, Pulsoni A, Rigacci L, Rupolo M, Zaja F, Zinzani PL, Barbui T,
Foa R. Quantitative PCR of bone marrow BCL2/IgH+ cells at diagnosis predicts treatment response and long-term outcome in follicular non-Hodgkin lymphoma.
Blood. 2005 May 1;105(9):3428-33. Epub 2005 Jan 6.
58. Arcaini L, Burcheri S, Rossi A, Passamonti F, Paulli M, Boveri E, Brusamolino E, Orlandi E, Molteni A, Pulsoni A, Cox MC, Orsucci L, Fabbri A, Frezzato M, Voso MT,
Zaja F, Montanari F, Pascutto C, Morra E, Cortelazzo S, Lazzarino M. Nongastric marginal-zone B-cell MALT lymphoma: prognostic value of disease
dissemination. Oncologist 2006; 11(3):285-291.
59. Arcaini L, Burcheri S, Rossi A, Paulli M, Bruno R, Passamonti F, Brusamolino E, Molteni A, Pulsoni A, Cox M, Orsucci L, Fabbri A, Frezzato M, Voso M, Zaja F,
Montanari F, Merli M, Pascutto C, Morra E, Cortelazzo S, Lazzarino M. Prevalence of HCV infection in nongastric marginal zone B-cell lymphoma of MALT. Ann
Oncol 2007; 18(2):346-350.
60. Arcaini L, Lazzarino M, Colombo N, Burcheri S, Boveri E, Paulli M, Morra E, Gambacorta M, Cortelazzo S, Tucci A, Ungari M, Ambrosetti A, Menestrina F, Orsucci
L, Novero D, Pulsoni A, Frezzato M, Gaidano G, Vallisa D, Minardi V, Tripodo C, Callea V, Baldini L, Merli F, Federico M, Franco V, Iannitto E, Integruppo Italiano
Linfomi. Splenic marginal zone lymphoma: a prognostic model for clinical use. Blood 2006; 107(12):4643-4649.
61. Baudo F, Caimi TM, Mostarda G, De Cataldo F, Morra E. Critical bleeding in pregnancy: A novel therapeutic approach to bleeding. Minerva Anestesiol 2006;
72:389-393.
62. Brusamolino E, Rusconi C, Montalbetti L, Gargantini L, Uziel L, Pinotti G, Fava S, Rigacci L, Pagnucco G, Pascutto C, Morra E, Lazzarino M. Dose-dense R-CHOP-14
supported by pegfilgrastim in patients with diffuse large B-cell lymphoma: a phase II study of feasibility and toxicity. Haematologica 2006; 91(4):496-502.
63. Cairoli R, Beghini A, Grillo G, Nadali G, Elice F, Ripamonti CB, Colapietro P, Nichelatti M, Pezzetti L, Lunghi M, Cuneo A, Viola A, Ferrara F, Lazzarino M,
Rodeghiero F, Pizzolo G, Larizza L, Morra E. Prognostic impact of c-KIT mutations in core binding factor leukemias: An Italian retrospective study. Blood 2006;
107:3463-3468.
64. Capello D, Cerri M, Muti G, Lucioni M, Oreste P, Gloghini A, Berra E, Deambrogi C, Franceschetti S, Rossi D, Alabiso O, Morra E, Rambaldi A, Carbone A, Paulli M,
Gaidano G. Analysis of immunoglobulin heavy and light chain variable genes in post-transplant lymphoproliferative disorders. Hematol Oncol 2006; 24(4):212219.
65. Carrafiello G, Lagana D, Nosari AM, Guffanti C, Morra E, Recaldini C, D'Alba MJ, Sonvico U, Vanzulli A, Fugazzola C. Utility of computed tomography (CT) and of
fine needle aspiration biopsy (FNAB) in early diagnosis of fungal pulmonary infections. Study of infections from filamentous fungi in haematologically
immunodeficient patients. Radiol Med (Torino) 2006; 111(1):33-41.
66. European Federation of Neurological Societies, Peripheral Nerve Society, Hadden RD, Nobile-Orazio E, Sommer C, Hahn A, Illa I, Morra E, Pollard J, Hughes RA,
Bouche P, Cornblath D, Evers E, Koski CL, Leger JM, Van den Bergh P, van Doorn P, van Schaik IN. European Federation of Neurological Societies/Peripheral
Nerve Society guideline on management of paraproteinaemic demyelinating neuropathies: report of a joint task force of the European Federation of
Neurological Societies and the Peripheral Nerve Society. Eur J Neurol 2006; 13(8):809-818.
67. Kimby E, Treon SP, Anagnostopoulos A, Dimopoulos M, Garcia-Sanz R, Gertz MA, Johnson S, LeBlond V, Fermand JP, Maloney DG, Merlini G, Morel P, Morra E,
Nichols G, Ocio EM, Owen R, Stone M, Blade J. Update on recommendations for assessing response from the Third International Workshop on Waldenstrom's
Macroglobulinemia. Clin Lymphoma Myeloma 2006; 6(5):380-383.
68. Montillo M, Tedeschi A, Miqueleiz S, Veronese S, Cairoli R, Intropido L, Ricci F, Colosimo A, Scarpati B, Montagna M, Nichelatti M, Regazzi M, Morra E.
Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia. J Clin Oncol
2006; 24(1):2337-2342.
69. Nosari A, Cairoli R, Ciapanna D, Gargantini L, Intropido L, Barate C, Scarpati B, Santoleri L, Nador G, Pezzetti L, Morra E. Efficacy of single dose pegfilgrastim in
enhancing the mobilization of CD34+ peripheral blood stem cells in aggressive lymphoma patients treated with cisplatin-aracytin-containing regimens. Bone
Marrow Transplant 2006; 38(6):413-416.
70. Piana F, Codecasa LR, Cavallerio P, Ferrarese M, Migliori GB, Barbarano L, Morra E, Cirillo DM. Use of a T-cell-based test for detection of tuberculosis infection
among immunocompromised patients. Eur Respir J 2006; 28(1):31-34.
Pagina 5 / 8 - Curriculum vitae di
Morra Enrica
Per maggiori informazioni su Europass: http://europass.cedefop.europa.eu
© Unione europea, 2002-2010 24082010
71. Treon SP, Gertz MA, Dimopoulos M, Anagnostopoulos A, Blade J, Branagan AR, Garcia-Sanz R, Johnson S, Kimby E, Leblond V, Fermand JP, Maloney DG, Merlini
G, Morel P, Morra E, Nichols G, Ocio EM, Owen R, Stone MJ. Update on treatment recommendations from the Third International Workshop on Waldenstrom's
macroglobulinemia. Blood 2006; 107(9):344272. Arcaini L, Paulli M, Burcheri S, Rossi A, Spina M, Passamonti F, Lucioni M, Motta T, Canzonieri V, Montanari M, Bonoldi E, Gallamini A, Uziel L, Crugnola M,
Ramponi A, Montanari F, Pascutto C, Morra E, Lazzarino M; Intergruppo Italiano Linfomi. Primary nodal marginal zone B-cell lymphoma: clinical features and
prognostic assessment of a rare disease. Br J Haematol. 2007 Jan;136(2):301-4.
73. Arcaini L, Burcheri S, Rossi A, Paulli M, Bruno R, Passamonti F, Brusamolino E, Molteni A, Pulsoni A, Cox MC, Orsucci L, Fabbri A, Frezzato M, Voso MT, Zaja F,
Montanari F, Merli M, Pascutto C, Morra E, Cortelazzo S, Lazzarino M. Prevalence of HCV infection in nongastric marginal zone B-cell lymphoma of MALT. Ann
Oncol. 2007 Feb;18(2):346-50.
74. Tedeschi A, Barate C, Minola E, Morra E. Cryoglobulinemia. Blood Rev. 2007 Feb 6;
75. Nosari A, Ravini M, Cairoli R, Cozzi P, Marbello L, Marenco P, Grillo G, Morra E. Surgical resection of persistent pulmonary fungus nodules and secondary
prophylaxis are effective in preventing fungal relapse in patients receiving chemotherapy or bone marrow transplantation for leukemia. Bone Marrow
Transplant. 2007 May;39(10):631-5.
76. Tedeschi A, Montillo M, Strocchi E, Cafro AM, Tresoldi E, Intropido L, Nichelatti M, Marbello L, Barate C, Camaggi CM, Morra E. High-dose idarubicin in
combination with Ara-C in patients with relapsed or refractory acute lymphoblastic leukemia: a pharmacokinetic and clinical study. Cancer Chemother
Pharmacol. 2007 May; 59(6):771-9.
77. Montagna M, Avanzini MA, Visai L, Locatelli F, Montillo M, Morra E, Regazzi MB. A new sensitive enzyme-linked immunosorbent assay (ELISA) for Alemtuzumab
determination: development, validation and application. Int J Immunopathol Pharmacol. 2007 Apr-Jun;20(2):363-71.
78. Corso A, Mangiacavalli S, Barbarano L, Alessandrino EP, Cairoli R, Morra E, Lazzarino M; on Behalf of the HOST Group. Limited feasibility of double transplant in
multiple myeloma: results of a multicenter study on 153 patients aged <65 years. Cancer. 2007 Jun 1;109(11):2273-8.
79. Passamonti F, Randi ML, Rumi E, Pungolino E, Elena C, Pietra D, Scapin M, Arcaini L, Tezza F, Moratti R, Pascutto C, Fabris F, Morra E, Cazzola M, Lazzarino M.
Increased risk of pregnancy complications in patients with essential thrombocythemia carrying the JAK2(V617F) mutation. Blood. 2007 Jul 15;110(2):485-9.;
80. Molica S, Montillo M, Ribatti D, Mirabelli R, Tedeschi A, Ricci F, Veronese S, Vacca A, Morra E. Intense reversal of bone marrow angiogenesis after sequential
fludarabine-induction and alemtuzumab-consolidation therapy in advanced chronic lymphocytic leukemia. Haematologica. 2007 Sep 1;
81. Zappasodi P, Nosari AM, Astori C, Ciapanna D, Bonfichi M, Varettoni M, Mangiacavalli S, Morra E, Lazzarino M, Corso A. DCEP chemotherapy followed by a
single, fixed dose of pegylated filgrastim allows adequate stem cell mobilization in multiple myeloma patients. Transfusion. 2008 Feb 1;
82. Passamonti F, Rumi E, Caramella M, Elena C, Arcaini L, Boveri E, Del Curto C, Pietra D, Vanelli L, Bernasconi P, Pascutto C, Cazzola M, Morra E, Lazzarino M. A
dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis. Blood. 2008 Jan 10;
83. Corso A, Mangiacavalli S, Barbarano L, Montalbetti L, Mazzone A, Fava S, Varettoni M, Zappasodi P, Morra E, Lazzarino M. Low efficacy of thalidomide in
improving response after induction in multiple myeloma patients who are candidates for high-dose therapy. Leuk Res. 2007 Dec 18;
84. Baudo F, de Cataldo F, Mostarda G, Ghirarduzzi A, Molinatti M, Pengo V, Poli D, Tosetto A, Tiraferri E, Morra E. Management of patients on long-term oral
anticoagulant therapy undergoing elective surgery: survey of the clinical practice in the Italian anticoagulation clinics. Intern Emerg Med. 2007 Dec;2(4):280-4.
85. Redaelli R, Corno AR, Somaini MG, Gechtman C, Caimi TM, Baudo F, Morra E. False incoagulable PT-INR results in oral anticoagulant therapy. Thromb Res. 2007
Nov 8;
86. Nosari A, Ravini M, Cairoli R, Cozzi P, Marbello L, Marenco P, Grillo G, Morra E. Surgical resection of persistent pulmonary fungus nodules and secondary
prophylaxis are effective in preventing fungal relapse in patients receiving chemotherapy or bone marrow transplantation for leukemia. Bone Marrow
Transplant. 2007 May;39(10):631-5. Epub 2007 Mar 26.
87. Arcaini L, Paulli M, Burcheri S, Rossi A, Spina M, Passamonti F, Lucioni M, Motta T, Canzonieri V, Montanari M, Bonoldi E, Gallamini A, Uziel L, Crugnola M,
Ramponi A, Montanari F, Pascutto C, Morra E, Lazzarino M; Intergruppo Italiano Linfomi. Primary nodal marginal zone B-cell lymphoma: clinical features and
prognostic assessment of a rare disease. Br J Haematol. 2007 Jan;136(2):301-4.
88. Cesana C, Klersy C, Brando B, Nosari A, Scarpati B, Scampini L, Molteni A, Nador G, Santoleri L, Formenti M, Valentini M, Mazzone A, Morra E, Cairoli R.
Prognostic value of circulating CD34(+) cells in myelodysplastic syndromes. Leuk Res. 2008 Nov;32(11):1715-23. Epub 2008 May 5.
89. Arcaini L, Montanari F, Alessandrino EP, Tucci A, Brusamolino E, Gargantini L, Cairoli R, Bernasconi P, Passamonti F, Bonfichi M, Zoli V, Bottelli C, Calatroni S,
Troletti D, Merli M, Pascutto C, Majolino I, Rossi G, Morra E, Lazzarino M. Immunochemotherapy with in vivo purging and autotransplant induces long clinical
and molecular remission in advanced relapsed and refractory follicular lymphoma. Ann Oncol. 2008 Jul;19(7):1331-5. Epub 2008 Mar 15.
90. Marbello L, Ricci F, Nosari AM, Turrini M, Nador G, Nichelatti M, Tedeschi A, Vismara E, Morra E. Outcome of hyperleukocytic adult acute myeloid leukaemia: a
single-center retrospective study and review of literature. Leuk Res. 2008 Aug;32(8):1221-7. Epub 2008 Mar 3. Review.
91. Zappasodi P, Nosari AM, Astori C, Ciapanna D, Bonfichi M, Varettoni M, Mangiacavalli S, Morra E, Lazzarino M, Corso A. DCEP chemotherapy followed by a
single, fixed dose of pegylated filgrastim allows adequate stem cell mobilization in multiple myeloma patients. Transfusion. 2008 May;48(5):857-60. Epub 2008
Feb 1.
92. Passamonti F, Rumi E, Caramella M, Elena C, Arcaini L, Boveri E, Del Curto C, Pietra D, Vanelli L, Bernasconi P, Pascutto C, Cazzola M, Morra E, Lazzarino M. A
dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis. Blood. 2008 Apr 1;111(7):3383-7. Epub 2008 Jan 10.
93. Corso A, Zappasodi P, Barbarano L, Petrucci MT, Palumbo A, Caravita T, Mangiacavalli S, Cafro AM, Varettoni M, Gay F, Morra E, Lazzarino M. Long term out
come in relapsed annd refractory multiple myeloma treated with thalidomide . Balancing efficacy an side effects. Leuk Res. 2009 Sep;33(9):e145-9. Epub 2009
Apr 16.
94.
Capello D, Rasi S, Oreste P, Veronnese S, Cerri M, Ravelli E, Rossi D, Minoia E, Colosimo A, Gambacorta M, Muti G, Morra E, Gaidano G. Molecular
characterization of post-transplant llymmphoproliferative disorders of donor origin occurring in liver transplant recipients. J Pathol. 2009 Aug;218(4):478-86.
Pagina 6 / 8 - Curriculum vitae di
Morra Enrica
Per maggiori informazioni su Europass: http://europass.cedefop.europa.eu
© Unione europea, 2002-2010 24082010
95.
Cairoli R, Ripamonti CB, Beghini A, Granata S, Grillo G, Brioschi M, Nadali G, Viola A, Cattaneo C, Inropido L, Ravelli E, Bertani G, Pezzetti L, Nichelatti M,
Marocchi A, Rossi G, Pizzolo G, Ferrara F, Nosari AM, Morra E. Total serum tryptase: a predictive marker for KIT mutation in acute myeloid leukemia. Leuk Res.
2009 Sep;33(9):1282-4. Epub 2009 Apr 29.
96.
Ricci F, Tedeschi A, Morra E, Montillo M. Fludarabine in the treatment of chronic lymphocytic leukemia: a review.Ther Clin Risk Manag. 2009 Feb;5(1):187-207.
Epub 2009 Mar 26.
97.
Cirasino L, Robino AM, Cattaneo M, Pioltelli PE, Pogliani EM, Terranova L, Morra E, Colombo P, Palmieri GA, Piscitelli P. Appropriate hospital management of
adult immune thrombocytopenic purpura patients in major Italian institutions in 2000-2002: a retrospective analysis. Blood Coagul Fibrinolysis. 2010
Jan;21(1):77-84.
98.
Corso A, Barbarano L, Mangiacavalli S, Spriano M, Alessandrino EP, Cafro AM, Pascutto C, Varettoni M, Bernasconi P, Grillo G, Carella AM, Montalbetti L,
Lazzarino M, Morra E. Bortezomib plus dexamethasone can improve stem cell collection and overcome the need for additional chemotherapy before
autologous transplant in patients with myeloma.Leuk Lymphoma. 2010 Feb;51(2):236-42.
99.
Passamonti F, Cervantes F, Vannucchi AM, Morra E, Rumi E, Pereira A, Guglielmelli P, Pungolino E, Caramella M, Maffioli M, Pascutto C, Lazzarino M, Cazzola
M, Tefferi A. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for
Myeloproliferative Neoplasms Research and Treatment). Blood. 2010 Mar 4;115(9):1703-8. Epub 2009 Dec 14.
100. Trojani A, Montillo M, Nichelatti M, Tedeschi A, Colombo C, Veronese S, Mura MA, Ricci F, Scarpati B, Colosimo A, Lodola M, Morra E. ZAP-70, IgVh, and
cytogenetics for assessing prognosis in chronic lymphocytic leukemia. Cancer Biomark. 2010 Jan;6(1):1-9.
101. Aspirin in pregnant patients with essential thrombocythemia: a retrospective analysis of 129 pregnancies. Passamonti F, Rumi E, Randi ML, Morra E, Cazzola
M. J Thromb Haemost. 2010 Feb;8(2):411-3.
102. Rinaldi A, Capello D, Scandurra M, Greiner TC, Chan WC, Bhagat G, Rossi D, Morra E, Paulli M, Rambaldi A, Rancoita PM, Inghirami G, Ponzoni M, Moreno SM,
Piris MA, Mian M, Chigrinova E, Zucca E, Favera RD, Gaidano G, Kwee I, Bertoni F. Single nucleotide polymorphism-arrays provide new insights in the
pathogenesis of post-transplant diffuse large B-cell lymphoma. Br J Haematol. 2010 May;149(4):569-77.
103. Pagano L, Caira M, Nosari A, Rossi G, Locatelli F, Viale P, Aversa F; Hema E-Chart Group Italy. Hema e-Chart: Italian Registry for prospective analysis of
epidemiology, management and outcome of febrile events in patients with hematological malignancies. J Chemother. 2010 Feb;22(1):20-4.
104. Corno AR, Campolo J, Redaelli R, Caimi TM, Mostarda G, Morra E, Nichelatti M. Automated APTT cycle for the rapid identification of plasma prekallikrein
deficiency. Thromb Res. 2010 Aug;126(2):e152-3. Epub 2010 Mar 6.
105. Cesana C, Klersy C, Scarpati B, Brando B, Volpato E, Bertani G, Faleri M, Nosari A, Cantoni S, Ferri U, Scampini L, Barba C, Lando G, Morra E, Cairoli R. Flow
cytometry vs cytomorphology for the detection of hematologic malignancy in body cavity fluids. Leuk Res. 2010 Aug;34(8):1027-34.
106. Tedeschi A, Vismara E, Ricci F, Morra E, Montillo M. The spectrum of use of rituximab in chronic lymphocytic leukemia. Onco Targets Ther. 2010 Nov 26;3:22746.
107. Montillo M, Ricci F, Tedeschi A, Vismara E, Morra E. Bendamustine: new perspective for an old drug in lymphoproliferative disorders. Expert Rev Hematol.
2010 Apr;3(2):131-48.
108. Brioschi M, Fischer J, Cairoli R, Rossetti S, Pezzetti L, Nichelatti M, Turrini M, Corlazzoli F, Scarpati B, Morra E, Sacchi N, Beghini A. Down-regulation of
microRNAs 222/221 in acute myelogenous leukemia with deranged core-binding factor subunits . Neoplasia. 2010 Nov;12(11):866-76.
109. Visani G, Breccia M, Gozzini A, Specchia G, Montefusco E, Morra E, Annunziata M, Camera A, Cavazzini F, Stagno F, Pregno P, Usala E, Santini V, Piccaluga PP,
Isidori A. Dasatinib, even at low doses, is an effective second-line therapy for chronic myeloid leukemia patients resistant or intolerant to imatinib. Results
from a real life-based Italian multicenter retrospective study on 114 patients. Am J Hematol. 2010 Dec;85(12):960-3.
110. Cirasino L, Robino AM, Cattaneo M, Pioltelli PE, Pogliani EM, Morra E, Colombo P, Palmieri GA. Reviewed diagnosis of primary and secondary immune
thrombocytopenic purpura in 79 adult patients hospitalized in 2000-2002. Blood Coagul Fibrinolysis. 2011 Jan;22(1):1-6.
111. Passamonti F, Cervantes F, Vannucchi AM, Morra E, Rumi E, Cazzola M, Tefferi A. Dynamic International Prognostic Scoring System (DIPSS) predicts progression
to acute myeloid leukemia in primary myelofibrosis. Blood. 2010 Oct 14;116(15):2857-8.
112. Arcaini L, Laszlo D, Rizzi S, Balzarotti M, Antoniazzi F, Zilioli VR, Guggiari E, Farina L, Todisco E, Bonfichi M, Alamos SM, Rossi G, Martinelli G, Morra E. Plerixafor
and G-CSF for PBSC mobilization in patients with lymphoma who failed previous attempts with G-CSF and chemotherapy: A REL (Rete Ematologica Lombarda)
experience. Leuk Res. 2011 Jan 26.
113. Capello D, Gloghini A, Martini M, Spina M, Tirelli U, Bertoni F, Rinaldi A, Morra E, Rambaldi A, Sinigaglia F, Larocca LM, Carbone A. Mutations of CD79A, CD79B
and EZH2 genes in immunodeficiency-related non-Hodgkin lymphomas. Br J Haematol. 2011 Jan 30.
114. Cesana C, Klersy C, Scarpati B, Brando B, Faleri M, Bertani G, Gatti A, Volpato E, Barba C, Ferri U, Scampini L, Grillo G, Lando G, Nosari A, Morra E, Cairoli R.
Flow cytometry and cytomorphology evaluation of hematologic malignancy in cerebrospinal fluids: comparison with retrospective clinical outcome. Ann
Hematol. 2011 Jan 7.
115. Montagna M, Montillo M, Avanzini MA, Tinelli C, Tedeschi A, Visai L, Ricci F, Vismara E, Morra E, Regazzi M. Relationship between pharmacokinetic profile of
subcoutaneously administered alemtuzumab and clinical response in patients with chronic lymphocytic leukemia. Haematologica. 2011 Feb 17.
116. Gambacorti-Passerini C, Antolini L, Mahon FX, Guihot F, Deininger M, Fava C, Nagler A, Della Casa CM, Morra E, Abruzzese E, D’Emilio A, Stagno F, le Coutre P,
Hurtado-Monroy R, Santini V, Martino B, Pane F, Piccin A, Giraldo P, Assouline S, Durosinmi MA, Leeksma O, Pogliani EM, Puttini M, Jang E, Reiffers J, Valsecchi
MG, Kim DW. Multicenter independent assesment of outcomes in chronic myeloid leukemia patients treated with imatinib. J Natl Cancer Inst. 2011 Apr 6;
103(7):553-61.
117. Treon SP, Merlini G, Morra E, Patterson CJ, Stone MJ. Report from the Sixth International Workshop on Waldenstrom’s Macroglobulinemia. Clin Lymphoma
Myeloma Leuk. 2011 Feb 1; 11 (1): 68-73.
Pagina 7 / 8 - Curriculum vitae di
Morra Enrica
Per maggiori informazioni su Europass: http://europass.cedefop.europa.eu
© Unione europea, 2002-2010 24082010
118. Greco A., Tedeschi A, Varettoni M, Nichelatti M, Paris L, Ricci F, Vismara E, Morra E. Factors predicting transformation of asymtomstic IgM monoclonal
gammopathy. Clin Lymphoma Myeloma Leuk. 2011 Feb 1; 11 (1): 77-9.
119. Brizio A, Nosari A, Lombardi G, Riva M, Cantoni S,Morra E, Oral voriconazole for neutropenia: a leukemia patient with probable pulmonary aspergillosis and
scedosporidiosis. J Chemother. 2011 Feb; 23 (1):53-4.
120. Visani G, Breccia M, Montefusco E, Morra E, Santini V, Isidori A. The incidence of pleural and pericardial effusion is not higher in patients receiving dasatinib at
low doses. (Reply). Haematologica 2011 Apr; 96(4):e23-4;
121. Varettoni M, Tedeschi A, Arcaini L, Pascutto C, Vismara E, Orlandi E, Ricci F, Corso A, Greco A, Mangiacavalli S, Lazzarino M, Morra E. Risk of second cancers in
Waldenstrom macroglobuline mia. Ann. Oncol. 2011 Apr 27
122. Marbello L, Riva M, Veronese S, Nosari AM, Ravano E, Colosimo A, Paris L, Morra E. Med Oncol.2011 May 24
123. Tedeschi A, Benevolo G, Varettoni M, Battista ML, Zinzani PL, Visco C, Meneghini V, Pioltelli P,Sacchi S, Ricci F, Nichelatti M, Zaja F, Lazzarino M, Vitolo U,
Morra E. Fludarabine plus cyclophosphamide and rituximab in Waldenstrom macroglobuline mia: An effective but myelosuppressive regimen to be offered to
patients with advanced disease. Cancer 2011 Jul 5
124. Ricci F, Tedeschi A, Montillo M. Morra E, Therapy –Related Myeloid Neoplasms in Chronic Lymphocytic Leukemia and Waldenstrom’s Macroglobulinemia.
Mediterr J Hematol Infect Dis. 2011; 3(1):e2011031. Epub 2011 Jul 9
125. Montillo M, Tedeschi A, Petrizzi VB, Ricci F, Crugnola M, Spriano M, Spedini P, Ilariucci F, Uziel L, Attolico I, Vismara E, De Blasio A, Zaccaria A, Morra E.An
open-label, pilot study of fludarabine, cyclophosphamide, and alemtuzumab (FCC) in relapsed/refractory patients with B-cell chronic lymphocytic leukemia.
Blood.2011, Prepublished on line, Jul 19.
126. Nosari A, Caimi TM, Zilioli V, Molteni A, Mancini V, Morra E. Celebral Hemorrhage Treated with Novoseven in Acute Promyelocytic Leukemia. Leuk Lymphoma.
2011 Jul 23.
127. Oliva EN, Piccin A, Mazzucconi MG, Morra E, Recine U, Pogliani EM, Pane F, Gobbi M, Gugliotta L, Krampera M, Cascavilla N, Cacciola R, Cacciola E, Fioritoni G,
Fanin R, Liberati AM, Angelucci E, Tura S. Quality of life in elderly patients with essential thrombocythaemia. An Italian multicentre study. Ann Hematol.2011
Oct. 1.
128. Tefferi A, Pardanani A, Gangat N, Begna KH, Hanson CA, Van Dyke DL, Caramazza D, Vannucchi AM, Morra E, Cazzola M, Pereira A, Cervantes F, Passamonti F.
Leukemia risk models in primary myelofibrosis: an International Working Group study. Leukemia. 2012 Jan 13. doi: 10.1038/leu.2011.374.
129.
Cesana C, Marbello L, Scarpati B, Calzavara E, Vanzulli A, Soriani S, Nosari A, Morra E. Erythroleukemia presenting with myeloid sarcoma of the lung as
detected by immunophenotypic analysis of bronchoalveolar lavage fluid. Leuk Res. 2012 Mar;36(3):e46-9.
130 . Hengeveld M, Suciu S, Karrasch M, Specchia G, Marie JP, Muus P, Petti MC, Rotoli B, Amadori S, Fioritoni G, Leoni P, Morra E, Thaler J, Resegotti L, Fazi P,
Vignetti M, Mandelli F, Zittoun R, de Witte T.Intensive consolidation therapy compared with standard consolidation and maintenance therapy for adults with
acute myeloid leukaemia aged between 46 and 60 years: final results of the randomized phase III study (AML 8B) of the European Organization for Research
and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups. Ann Hematol.
2012 Jun;91(6):825-35.
Pagina 8 / 8 - Curriculum vitae di
Morra Enrica
Per maggiori informazioni su Europass: http://europass.cedefop.europa.eu
© Unione europea, 2002-2010 24082010